SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound on elevated volume has traders speculating about a news leak or buyout, partly reading CEO Angelos Stergious anniversary message as a signal; neither claim is confirmed. The main underlying focus is the Phase 3 REGAL trials final analysis, triggered at 80 deaths after 78 were last disclosed: bulls interpret the wait as a possible sign of longer survival, while skeptics note the results remain uncertain.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp move is drawing attention as shares push above recent technical resistance, while traders point to anticipated DM1 and FSHD siRNA data as potential catalysts. Some see strength or possible short covering, while others caution that past rallies have faded and no new catalyst is confirmed in the discussion.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs weak, range-bound trading and exposure to broader crypto-market selling dominate the discussion, with many traders frustrated by failed rallies and warning of more downside. Others view the pullback as consolidation and say they are accumulating or holding, while watching technical resistance and Bitcoins direction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are under pressure after a quarterly earnings beat failed to offset a narrowed full-year profit outlook that left the midpoint unchanged; weaker U.S. sales and market share also weighed on the reaction. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and a new buyback, and focusing on the lack of a higher profit outlook.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and raised outlook have been met with a sharp selloff, prompting frustration and debate over why strong demand and guidance have not supported the shares. Traders point to profit-taking and elevated expectations, while cost pressures, weaker cash conversion and an insurance-unit loss have raised questions about margins and the quality of the results.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena's Partnership Strategy: Growth Driver or Limitation?

PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years 

Equity

Executive severance changes from June and Sellas’ sizable ASH conference booth have fueled deal speculation.

Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch

Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its oncology portfolio and pipeline across a broad range of solid tumors at the European Society for Medical Oncology (ESMO) 2026 Congress to be held October 23-27 in Madrid, Spain. Across 12 oral presentations and...

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

BMY Reports Mixed Phase III Trial Results, Stock Down

Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Bristol Myers Squibb (BMY) reached $57.6 at the closing of the latest trading day, reflecting a -2.58% change compared to its last close.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bearish Sentiment

<ul class="summary-bullets"><li>CEO Angelos Stergiou marked Sellas’ 15th anniversary, pointing to its “next chapter” with GPS and SLS009.</li><li>Retail investors floated $40 billion-$120 billion valuation scenarios and share-price predictions ranging from $100 to $540.&nbsp;</li><li>Investors await Regal’s final-analysis trigger of 80 deaths, following Sellas’ disclosure of 78 events as of May 11.</li></ul>Retail investors in Sellas Life Sciences (SLS) are floating multibillion-dollar buyout scenarios and steep share-price gains after CEO Angelos Stergiou marked the company’s 15th anniversary with a post about its “next chapter.”<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 5% on Monday to $10.49, snapping three straight losing sessions.&nbsp;<h2 class="st-heading-2">Sellas CEO Points To ‘Best Chapters’ Ahead</h2>In his LinkedIn post, Stergiou reflected on Sellas’ growth from a private startup into a public biotech advancing investigational cancer treatments GPS and SLS009.“Reaching 15 years isn't just about celebrating our history; it is about stepping into our next chapter with even greater focus, drive, and resolve,” he said. He acknowledged past setbacks and thanked shareholders, employees and trial participants, while reaffirming the company’s commitment to patients.“Our mission remains deeply personal, and our promise to the patients we aim to serve is steadfast. We look forward, God willing, to the best chapters that are still to be written with GPS and SLS009,” he added.<h2 class="st-heading-2">SLS Retail Floats Multibillion-Dollar Buyout Scenarios</h2>On Stocktwits, retail sentiment for SLS slipped to ‘bearish’ from ‘bullish’ levels a day ago amid a 258% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_725c1f1d42.png" alt="sls ss.png" width="633" height="343"><figcaption>SLS sentiment and message volume as of October 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Reformed_MMAT_investor/message/666881029">said</a>: “My opinion, Dr. Stergiou’s message was a master-class at reassuring EVERYONE that all is well.”A user<a href="https://stocktwits.com/Gebinator/message/666869438"> also&nbsp;floated</a> a minimum $40 billion valuation. Another user<a href="https://stocktwits.com/55X_ROI_Q1_2026/message/666882686">&nbsp;argued</a> for a $50 billion valuation, calling a $247-per-share figure. A separate user<a href="https://stocktwits.com/vlucky16/message/666866929">&nbsp;proposed</a> a $120 billion buyout scenario and also predicted a share price of $540-plus.Across bullish share-price predictions, including scenarios tied to clinical results, targets ranged from $100 to over $540. Discussing buyout news in case of favorable data, one user&nbsp;<a href="https://stocktwits.com/AIALuckyDog/message/666879536">said</a>: “If BO news post good data then there’s no stopping this beast (really no explanation required as it could go full berserker mode).” BO means buyout.Another user challenged the lofty valuations and&nbsp;<a href="https://stocktwits.com/noviceEve/message/666855368">said</a>: “I will be so glad to get out of this ticker when it hits $15 again.”<h2 class="st-heading-2">Retail Searches Filings, Conference Plans For Clues</h2>The CEO’s message comes as investors have been&nbsp;searching for potential deal signals in recent months. In June, a filing disclosed changes to executive severance arrangements, including lump-sum payment provisions for Stergiou.For CFO John Burns and chief development officer Dragan Cicic, qualifying departures within one month before or one year after a change of control would trigger 15 months of salary, the annual target bonus, up to 18 months of health-coverage reimbursements and full vesting of unvested equity.&nbsp;Sellas’ conference plans have provided another talking point. The company is listed at Booth 138, with a 20-by-30-foot space, for the Dec.12- Dec.15 American Society of Hematology (ASH) meeting in New Orleans. Major exhibitors include Eli Lilly, Pfizer, Merck, AbbVie and Bristol Myers Squibb. The booth size has fueled speculation about a partnership or acquisition.<h2 class="st-heading-2">Sellas Regal Trial And SLS009 Data In Focus</h2>Currently, investors are awaiting data from Sellas’ two lead programs. The Phase 3 Regal trial is testing GPS, an immunotherapy targeting WT1, in acute myeloid leukemia (AML) patients who achieved a second complete remission following salvage treatment. Its final-analysis process is triggered by 80 deaths. Sellas reported 78 events as of May 11. Reaching 80 precedes database lock, data review and analysis before results are disclosed.&nbsp;The company also expects fourth-quarter topline data from its 80-patient Phase 2 SLS009 study in newly diagnosed AML, including patients with early resistance to azacitidine and venetoclax. SLS009 is also being explored in pancreatic cancer. Preclinical findings from last month showed 17.9% apoptosis (programmed cell death) in a patient-derived tumor model resistant to Daraxonrasib, versus 2.8% with Daraxonrasib alone. Combining the drugs raised apoptosis to 36.5% and necrosis to 30.6%.&nbsp;SLS stock has surged 178% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avgo-stock-10-year-docomo-deal-retail-on-edge-ceo-ai-casino-remarks/cZxqiudRBuJ">AVGO Stock Edges Up Overnight After 10-Year Docomo Deal, But Retail Stays On Edge Over CEO’s AI ‘Casino’ Remarks&nbsp;</a>

Representative Image (Photo credit: Getty Images)

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years

Abbvie Inc

Lilly(Eli) & Co

Merck & Co Inc

Pfizer Inc

SPDR S&P Biotech ETF

Track BMY stock price, charts, news and real-time market activity on Stocktwits. Join the BMY message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Bristol-Myers Squibb Co stock.

BMY Stock Price Today - Bristol Myers Squibb News, Charts, Retail Sentiment

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$61.40
Prev Close	$58.83
Open	$59.66
Dividend Yield	4.62%
50-Day Moving Average	$63.39
Beta	0.29
Avg. Volume	11.43M
PE Ratio	12.96

52-Week High	$68.64
52-Week Low	$42.52
Market Capitalization	$120.17B
EPS (Annual)	$3.46
Price to Book	5.39
Revenue Per Employee	$1.48M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMY Fundamentals